721 completed, 166 recruiting, 151 active not recruiting, 111 terminated. 337 Phase 1, 317 Phase 2, 305 Phase 3, 67 Phase 4, 24 Not applicable.
By phase and status
Phase Trials Status Phase 1 337 Completed 183 , Active not recruiting 50 , Terminated 50 , Recruiting 38 , Withdrawn 10 , Not yet recruiting 5 , Unknown 1 Phase 2 317 Completed 142 , Recruiting 72 , Active not recruiting 48 , Terminated 35 , Not yet recruiting 10 , Withdrawn 8 , Enrolling by invitation 2 Phase 3 305 Completed 200 , Active not recruiting 45 , Recruiting 29 , Terminated 13 , Withdrawn 8 , Not yet recruiting 5 , Enrolling by invitation 3 , Unknown 2 Phase 4 67 Completed 39 , Recruiting 9 , Terminated 7 , Unknown 7 , Active not recruiting 2 , Withdrawn 2 , Not yet recruiting 1 Not applicable 24 Completed 15 , Active not recruiting 3 , Unknown 3 , Not yet recruiting 1 , Recruiting 1 , Withdrawn 1 Early Phase 1 4 Active not recruiting 1 , Completed 1 , Not yet recruiting 1 , Terminated 1
Follow AbbVie: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Study to Learn How Effective, Safe, and Tolerable Upadacitinib is for Young Participants With Non-segmental Vitiligo Upadacitinib, Placebo for Upadacitinib - Non-Segmental Vitiligo Phase 3 Not yet recruiting 154 2027-01-28 2026-10-27
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer Telisotuzumab Adizutecan, Docetaxel, Ramucirumab - Non-Squamous Non-Small Cell Lung Cancer Phase 3 Not yet recruiting 660 2027-01-06 2026-10-05
Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations Ibrutinib Oral Tablet, Venetoclax Oral Tablet, Epcoritamab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Phase 2 Not yet recruiting 44 2026-12-31 2026-07-31
A Study to Evaluate the Safety and Efficacy (How Well the Study Treatment Works) of ABBV-2294 in Adult Participants With Systemic Sclerosis That Are Currently Receiving Local Standard of Care Treatment, and to Determine the Best Dose of ABBV-2294 to be Evaluated Further. ABBV-722, Upadacitinib, Placebo for ABBV-722 - Systemic Sclerosis Phase 2 / Phase 3 Not yet recruiting 580 2026-12-11 2026-11-12
Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis ABBV-722, Upadacitinib - Rheumatoid Arthritis Phase 2 Not yet recruiting 250 2026-12-07 2026-11-10
A Study to Assess Targeted Therapies for Treatment of Adults With Moderate to Severe Psoriasis Risankizumab, ABBV-295, ABBV-295 Placebo - Moderate to Severe Psoriasis Phase 2 Not yet recruiting 105 2026-12-03 2026-11-12
Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma Etentamig, Isatuximab, Bortezomib + Lenalidomide + Dexamethasone - Myeloma Multiple, Myeloma Phase 1 / Phase 2 Not yet recruiting 220 2026-12-01 2026-05-20
Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy Epcoritamab, Lenalidomide - Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Refractory Large B-cell Lymphoma (LBCL) Phase 2 Not yet recruiting 55 2026-12-01 2026-09-10
Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutations Upadacitinib, Placebo - JAK1 GOF, STAT1 GOF Phase 1 / Phase 2 Not yet recruiting 30 2026-12-01 2026-11-12
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma Etentamig, Pomalidomide, Daratumumab - Relapsed or Refractory Multiple Myeloma Phase 3 Not yet recruiting 520 2026-11-30 2026-07-27
Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) Amyloidosis Etentamig, Daratumumab, Cyclophosphamide - Amyloid Light Chain (AL) Amyloidosis Phase 3 Not yet recruiting 370 2026-11-29 2026-08-28
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Alveltamig and Atezolizumab for Adults Participants With Extensive Stage-Small Cell Lung Cancer Alveltamig, Atezolizumab, ABBV-706 - Extensive Stage-Small Cell Lung Cancer (ES-SCLC) Phase 2 Not yet recruiting 80 2026-11-20 2026-10-26
M4 Receptor PET Radioligand Validation Study in Healthy Adults [11C]ABBV-112i - Healthy Volunteers Early Phase 1 Not yet recruiting 6 2026-11-10 2026-11-12
A Study to Assess the Adverse Events and How Oral ABBV-1606 Moves Through the Body of Healthy Adult Participants. ABBV-1606, Placebo - Healthy Volunteer Phase 1 Not yet recruiting 40 2026-11-10 2026-11-13
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Tarlatamab and Atezolizumab in Adult Participants With Extensive Stage-Small Cell Lung Cancer ABBV-706, Tarlatamab, Atezolizumab - Extensive Stage-Small Cell Lung Cancer Phase 2 Not yet recruiting 80 2026-11-04 2026-10-26
Study to Assess Adverse Events and How Oral ABBV-1162 Moves Through the Body of Healthy Adults ABBV-1162, Placebo - Healthy Volunteers Phase 1 Not yet recruiting 40 2026-11-02 2026-09-22
Real-World Study of Mirvetuximab Soravtansine in Adult Participants With Platinum-Resistant FRα-Positive Ovarian, Fallopian Tube, and Peritoneal Cancer Platinum-Resistant FRα-Positive Ovarian Cancer, Platinum-Resistant FRα-Positive Fallopian Tube Cancer Recruiting 500 2026-10-21 2026-10-27
Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis Upadacitinib - UC - Ulcerative Colitis Phase 4 Not yet recruiting 50 2026-10-15 2026-09-24
A Study to Assess How Intravenous and Subcutaneous Administrations of Trosunilimab Move Through the Body of Healthy Adult Participants Trosunilimab - Healthy Volunteer Phase 1 Recruiting 60 2026-10-13 2026-11-09
A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With Moderate to Severe Upper Facial Lines TrenibotulinumtoxinE and OnabotulinumtoxinA, Placebo, OnabotulinumtoxinA - Upper Facial Lines, Glabellar Lines Phase 2 Recruiting 300 2026-10-08 2026-11-05
Showing 20 of 1253. Sign in to see all of them.
Conditions studied Neoplasms (143) · Hepatitis C (87) · Hepatitis C, Chronic (80) · Leukemia, Myeloid, Acute (68) · Psoriasis (60) · Crohn Disease (57) · Arthritis, Rheumatoid (56) · Colitis, Ulcerative (47) · Carcinoma, Non-Small-Cell Lung (42) · Leukemia, Lymphocytic, Chronic, B-Cell (42) · Multiple Myeloma (41) · Recurrence (41) · Parkinson Disease (34) · Dermatitis, Atopic (33) · Arthritis, Psoriatic (29)
Interventions venetoclax (137) · upadacitinib (72) · risankizumab (71) · Adalimumab (54) · Dexamethasone (46) · Ribavirin (40) · ombitasvir (40) · dasabuvir (39) · paritaprevir (39) · Carboplatin (31) · glecaprevir and pibrentasvir (29) · Azacitidine (28) · Rituximab (28) · budigalimab (28) · Botulinum Toxins, Type A (25)
Countries United States (726) · Spain (278) · Canada (271) · Germany (256) · Japan (232) · Australia (228) · France (222) · United Kingdom (213) · Italy (210) · Israel (188) · Poland (160) · South Korea (159) · Belgium (158) · Taiwan (144) · Puerto Rico (142)
Top investigators Eric Cohen, MD (4) · Andrey Strugovschikov, MD (3) · Armen Asatryan, MD (3) · Emily Dumas, PhD (3) · Susumu Matsuki, BS (3) · Yan Luo, MD (3)
Results publications PMID 40875187 , PMID 30739368 , PMID 36754548 , PMID 30977945 , PMID 37982966 , PMID 30012435 , PMID 30923816 , PMID 37945286 , PMID 31568620 , PMID 34041702 , PMID 30529905 , PMID 31610021 , PMID 35829925 , PMID 31054118 , PMID 31667790 , PMID 34878624 , PMID 36715850 , PMID 37308218 , PMID 30868245 , PMID 33115760 , PMID 36125701 , PMID 36178584 , PMID 31023700 , PMID 34921669 , PMID 35174470 , PMID 36794283 , PMID 38620092 , PMID 38683479 , PMID 38863178 , PMID 39624020 , PMID 41264726 , PMID 41763462 , PMID 27411694 , PMID 29290251 , PMID 29476499 , PMID 29909549 , PMID 29982805 , PMID 32621325 , PMID 32945631 , PMID 33650259 , PMID 33963686 , PMID 35714786 , PMID 37043227 , PMID 37224198 , PMID 37247226 , PMID 37368103 , PMID 38492903 , PMID 38492904 , PMID 38982567 , PMID 39054592
NIH funding 2023 (61) , 2016 (43) , 2015 (41) , 2014 (38) , 2019 (31) , 2017 (26) , 2025 (21) , 2018 (18) , 2009 (4) , 2008 (2) , P30CA060553 (2) , 4UH3TR003908 (1) , K08AR080844 (1) , K23AR080043 (1) , P30CA072720 (1)